



Andrew Fein Joins H.C. Wainwright & Co., LLC as Senior Biotechnology Analyst

NEW YORK, May 29, 2013 - H.C. Wainwright & Co., LLC ("HCW") today announced that it has hired Andrew S. Fein as Managing Director, Senior Biotechnology Analyst, to cover companies in the biotechnology and life sciences sectors.

Mr. Fein, who will be based in HCW's New York office, has 13 years of experience in healthcare and biotechnology equity research. He was previously a Senior Analyst at Chardan Capital Markets and held prior research positions at Jefferies, Piper Jaffrey, Collins Stewart, Leerink Swann and JP Morgan.

"The addition of Andrew Fein further demonstrates HCW's commitment to the biotechnology and life sciences sectors," said Mark Viklund, Chief Executive Officer of HCW. "Andrew's deep domain expertise across multiple disciplines within biotechnology enhances our ability to serve our institutional clients with regard to investment opportunities in the space."

About H.C. Wainwright & Co., LLC

H. C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H. C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H. C. Wainwright was established in 1868 and is headquartered in New York City.

Contact:

H.C. Wainwright & Co., LLC

430 Park Avenue, 4th Floor
New York, New York 10022
212-356-0500

info@hcwco.com

www.hcwco.com